OncoMatch/Clinical Trials/NCT05802121

Akkermansia Muciniphilia and Metabolic Side Effects of ADT

Is NCT05802121 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Apple Cider Vinegar for prostate cancer.

Early Phase 1RecruitingWestern UniversityNCT05802121Data as of May 2026

Treatment: Apple Cider Vinegar — The overriding objectives of this study are: 1. Primary outcomes: 1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to a standard of care arm. 2. To confirm tolerability and assess for side effects of oral acetate supplementation. 2. Secondary outcomes: 1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Required: Stage TANY, NANY (TNM)

Metastatic disease required

TNM stage Tany, Nany, M1

Prior therapy

Cannot have received: androgen deprivation therapy

Lab requirements

Liver function

Inadequate liver function (>2x upper limit of normal) excluded

Inadequate liver function (>2x upper limit of normal)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify